Choice ✔ investment

Choose stocks

Create and
share portfolios

Study reporting
public companies

ADRO - Company Financial Ratios

Aduro Biotech Inc.

Aduro Biotech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body`s natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation clinical trial and Phase Ib dose escalation clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase II clinical trial in combination with pembrolizumab, an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical

United States    http://www.aduro.com
Healthcare Biotechnology NASDAQ | Nasdaq Global Select

1.464 15.34

period
2021 14.60 1 180.19 - 20.94 0.00 0.00 4.01 0.000 0.00 4.69 8.38 - 14.21 - 73.77
2019 1.35 108.00 - 1.31 0.01 1.65 0.000 0.00 3.44 6.27 - 28.28 - 125.58
2018 2.72 214.00 - 2.25 0.02 1.58 0.000 0.00 1.64 14.21 - 26.67 - 70.47
2017 6.70 488.00 - 5.32 0.04 2.06 0.000 0.00 0.87 28.33 - 20.64 - 38.68
2016 11.15 727.00 - 7.98 0.05 3.20 0.000 0.00 0.93 14.34 - 20.78 - 40.11
2015 14.48 647.00 152.55 - 16.51 0.08 2.47 0.000 0.00 0.84 8.87 - 8.14 - 14.99